MicroCapClub member Marc Robins, author of The Emerging Era of MicroCaps series, joins me on the program. During this program Marc talks about how the microcap space has changed over the past 40 years, and even though much of the change has been “for the worse”, the opportunity in microcaps is still immense. The OTC Markets Group (OTCM) presented at our first ever MicroCapClub Member Meetup in Philadelphia last week, and Marc and I talk a bit about how the OTC Markets is bringing more transparency to the microcap space. (Click Play Arrow Below) Read More …
-
MicroCapClub Radio Program Episode 19
Posted April 11, 2013 By Ian Cassel in Blog, Broadcasts, Radio With | No Comments
-
MicroCapClub Interview with Closed-End Fund Pioneer Tom Herzfeld
Posted March 12, 2013 By Ian Cassel in Blog, Broadcasts, Interviews With | No Comments
Tom Herzfeld is Chairman and President of Thomas J. Herzfeld Advisors, Inc., and The Herzfeld Caribbean Basin Fund (NASDAQ: CUBA). He began his career in the securities industry in the 1960′s and formed a New York Stock Exchange member firm in 1970. Tom is widely considered to be the leading expert in the field of closed-end funds. He is author of the first textbook published on the subject The Investor’s Guide to Closed-End Funds (McGraw-Hill, 1979), as well as five other books dedicated to the industry. During this interview, we cover a broad range of topics relating closed-end funds, Cuba, and even some microcap Cuba plays. (Click the Play button below to Listen). Read More …
-
MicroCapClub Interview with Adam Epstein Author of The Perfect Corporate Board
Posted February 22, 2013 By Ian Cassel in Blog, Broadcasts, Interviews With | No Comments
Adam Epstein is a corporate director, and a special advisor to small-cap companies through his firm, Third Creek Advisors, LLC (“TCA”). He is the author of The Perfect Corporate Board: A Handbook for Mastering the Unique Challenges of Small-Cap Companies (New York: McGraw Hill, 2012). Prior to founding TCA, Mr. Epstein co-founded and was a principal of Enable Capital Management, LLC (“ECM”). During his tenure, ECM’s special situation hedge funds invested in more than 500 small-cap financings in the United States, the European Union, and Australasia. During this interview, we cover a broad range of topics relating to micro-smallcap companies. (Click the Play button below to Listen). Read More …
-
MicroCapClub Invitational: Vertex Energy (VTNR)
Posted February 13, 2013 By Ian Cassel in Blog, Broadcasts, Company Presentations, MicroCapClub Invitational 2013 With | No Comments
Vertex Energy (VTNR) is a vertically integrated hydrocarbon recovery company that has profitably grown revenues from $38m in 2009 to $110m in 2011. The company owns and operates a network of used motor oil collectors and aggregators, and then refines this feedstock using the company’s proprietary TCEP technology into higher value end products. The company has been expanding organically and by way of strategic acquisitions to broaden its footprint. Recovering, recycling and reusing hydrocarbons, plastics, and chemicals, has been a very hot area for investors the last couple of years. Several mergers and acquisitions in the space have made Vertex Energy a potential target. Heckmann (HEK) acquired Thermal Fluids in 2011, followed by Clean Harbor’s (CLH) acquisition of Safety-Kleen a few months ago. Heritage-Crystal Clean (HCCI), an industry comparable trades at over 20x 2013 EPS estimates. Vertex Energy has flown under the radar even while producing a more impressive growth curve then its larger peers. While the peer group trades at 20x 2013 analyst estimates, Vertex trades at 6x 2013 estimates, and that’s the opportunity. Listen to CEO Ben Cowart as he tells the story. Read More …
-
MicroCapClub Invitational: BioSyent (RX.V)
Posted February 11, 2013 By Ian Cassel in Blog, Broadcasts, Company Presentations, MicroCapClub Invitational 2013 With | No Comments
BioSyent (RX.V or BIOYF) is a rapidly growing pharmaceutical company that acquires or in-licenses proven drugs and markets them in Canada. Their business model is to build and sell a portfolio of products that have a peak penetration potential that is too small for major pharmaceutical companies. What has fascinated us about BioSyent is their ability to consistently grow revenue and earnings. In fact, their pharmaceutical sales have grown sequentially for the past 12 quarters, which is very rare in the microcap space. In 2012 they announced several new products that they have added to their portfolio plus they have a nice pipeline of additional products that we expect to further fuel their growth. In the most recent quarter they grew revenues 60% and net income 79% year/year. Listen to CEO Rene Goehrum as he tells the story. Read More …
